Table 1.
Cytogenetic and molecular responses in patients with CML before and after dasatinib treatment.
| No. | Sex | Age (years) | Pre-das treatment |
Time interval |
Cytogenetic response |
Molecular response(BCR-ABL/ABL IS) |
Time of Continued Das treatment |
|---|---|---|---|---|---|---|---|
| 1, 2 | Pre-das, after-das | Pre-das, after-das | |||||
| 1 | Male | 17 | Imatinib for 6 months | 62 days, 12 hours | MCR, CCyR(Ph+ = 40%), (Ph+ = 0%) | 14.097%, 0.087% (MMR) | 5 months |
| 2 | Male | 44 | Imatinib for 43 monthsand then nilotinib for 6 months | 77days, 8 hours | CCyR, CCyR(Ph+ = 0%), (Ph+ = 0%) | 0.000%, 0.000%(MR5), (MR5) | 5 months |
| 3 | Female | 44 | Imatinib for 6 months | 22 days, 12 hours | MCR, CCyR(Ph+ = 50%), (Ph+ = 0%) | 6.657%, 0.010% (MR4) | 4 months |
| 4 | Male | 61 | Imatinib for 53 monthsand then nilotinib for 8 months | 15 days, 6 hours | CCyR, CCyR(Ph+ = 0%), (Ph+ = 0%) | 4.166%, 0.030% (MMR) | 4 months |
| 5 | Male | 32 | Imatinib for 10 months | 3 days, 8 hours | CCyR, CCyR(Ph+ = 0%), (Ph+ = 0%) | 0.246%, 0.000% (MR5) | 3 months |
| 6 | Male | 52 | Imatinib for 2 monthsand then no treatment for 22 months (private economics reason) | 33 days, 5 hours | MCR, CCyR(Ph+ = 100%), (Ph+ = 0%) | 32.000%, 0.000% (MR5) | 3 months |
| 7 | Female | 56 | Imatinib for 12 months | 20 days, 8 hours | MCR, MCR(Ph+ = 52.780%), (Ph+ = 85%) | 16.633%, 3.380% | 4 months |
| 8 | Male | 45 | Imatinib for 3 months | 60 days, 3 hours | MCR, CCyR(Ph+ = 100%), (Ph+ = 0%) | 43.800%, 15.576% | 3 months |
| 9 | Male | 47 | Imatinib for 8 months | 31 days, 8 hours | MCR, MCR(Ph+ = 100%), (Ph+ = 90%) | 52.085%, 41.788% | 3 months |
Time interval 1: time interval between the time point of the first blood test for T-cell subtypes and the start date of dasatinib treatment.
Time interval 2: time interval between the time point of dasatinib intake and the time point of a blood test on the day of the blood test for T-cell subtypes.
Abbreviations: das, dasatinib; pre-das, before treatment with dasatinib; after-das, after treatment with dasatinib; CCyR, complete cytogenetic response; MCR, minor cytogenetic response; MMR, major molecular response; MR4, molecular response 4; MR5, molecular response 5; Ph+, Ph-positive metaphases.
Note: Because of the absence of CD8+T data from the ninth patient, we only analyzed CD8+T data in the first eight patients, including six who achieved better response levels and the other two patients who did not show improved response levels after dasatinib treatment.